RBM26

Across TCGA pan-cancer cohorts, RBM26 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBM26 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBM26 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBM26 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where RBM26 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.231	0.818	.004	39	view →
PDAC	DFS	Quartile	All	0.957	0.677	.007	17	view →
LUAD	DFS	Quartile	II,III,IV	0.967	0.706	.010	14	view →
CCRCC	DFS	Median	All	0.864	0.731	.044	3	view →
LSCC	OS	Median	All	0.874	0.713	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RBM26–HNSC (DFS)

Open the HNSC breakdown →